In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.
AUTOR(ES)
Naik, S
RESUMO
The in vitro activities of 12 macrolide compounds against 28 Mycobacterium avium complex strains isolated from patients with acquired immunodeficiency syndrome were determined by the conventional proportion method and by the BACTEC method. Clarithromycin (A-56268; TE-031), a new macrolide compound, was the most active agent tested, inhibiting 90% of strains at an MIC of 4 micrograms/ml by the BACTEC method. Roxithromycin (RU 28965) and erythromycylamine inhibited 90% of strains at 16 micrograms/ml. The organisms showed high levels of resistance to most other macrolide compounds.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172713Documentos Relacionados
- In Vitro Activities of Several Diaminomethylpyridopyrimidines against Mycobacterium avium Complex
- In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex.
- Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.
- Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex.
- Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.
